Products Targeting Alzheimer's, Duchenne & COVID-19 Among New EU Filings
Executive Summary
EU marketing authorization applications have been submitted for a number of new drugs, including Eli Lilly’s donanemab, Italfarmaco's givinostat and Arcturus Therapeutics/CSL’s ARCT-154.
You may also be interested in...
New EU Filings
Elafibranor, Ipsen/Genfit’s investigational oral, once-daily drug for primary biliary cholangitis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
New EU Filings
Imetelstat, Geron’s investigational treatment for transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
New EU Filings
Givinostat, Italfarmaco’s investigational treatment for Duchenne muscular dystrophy, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.